002099.SZ
海翔药业
SZSE · Healthcare · C 制造业 · CN
CNY 5.05
−3.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.9B | 1.9B | 1.9B | 2.2B | 2.7B |
| Cost of Revenue | 1.4B | 1.4B | 1.4B | 1.9B | 2.0B |
| Gross Profit | 464.5M | 454.8M | 518.3M | 304.6M | 720.3M |
| Operating Expenses | |||||
| R&D Expense | 114.5M | 116.9M | 129.4M | 115.6M | 144.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 315.6M | 308.3M | 307.5M | 324.9M | 402.4M |
| Selling & Marketing Expense | 32.0M | 28.7M | 33.3M | 29.2M | 26.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 529.1M | 491.3M | 439.1M | 466.1M | 492.4M |
| Cost and Expenses | 1.9B | 1.9B | 1.9B | 2.3B | 2.5B |
| Operating Income (EBIT) | (70.6M) | (80.0M) | (336.1M) | (464.2M) | 109.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (70.6M) | (84.1M) | (336.9M) | (466.2M) | 100.8M |
| Income Tax Expense | 5.2M | 9.7M | (3.0M) | (44.6M) | 14.7M |
| Bottom Line | |||||
| Net Income | (73.9M) | (91.1M) | (330.3M) | (420.1M) | 88.0M |
| Earnings from Cont. Ops | (75.8M) | (93.8M) | (333.9M) | (421.6M) | 86.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (73.9M) | (91.1M) | (330.3M) | (420.1M) | 88.0M |
| Per Share | |||||
| Basic EPS | (CN¥0.05) | (CN¥0.06) | (CN¥0.21) | (CN¥0.26) | CN¥0.05 |
| Diluted EPS | (CN¥0.05) | (CN¥0.06) | (CN¥0.21) | (CN¥0.26) | CN¥0.05 |
| Revenue Per Share | CN¥1.41 | CN¥1.23 | CN¥1.23 | CN¥1.34 | CN¥1.54 |
| Shares | |||||
| Basic Shares Outstanding | 1.3B | 1.5B | 1.6B | 1.6B | 1.8B |
| Diluted Shares Outstanding | 1.3B | 1.5B | 1.6B | 1.6B | 1.8B |
| Profitability Metrics | |||||
| EBITDA | — | 257.7M | 3.7M | (102.9M) | 441.5M |
| D&A | — | 337.8M | 339.8M | 361.3M | 332.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026